LRP1B and metastatic melanoma: In a retrospective review of patients with metastatic melanoma treated with ICI, LRP1b mutation was found to significantly correlate with response, being present in 11/32 (34%) of responders compared to 1/33 (3%) in non‐responders (P < 0.001).31 The authors hypothesized that, given LRP1b's size and genomic instability, it may serve as a single‐gene surrogate for total mutational load, having also found LRP1b‐mutated patients to have a significantly higher mutational load compared to those without.